Moreover, GATA3 positivity maintained the ability to stratify patients with a better prognosis, particularly in BC subgroups with positive ER (HR 0.77, p = 0.046), positive PR (HR 0.74, p = 0.022), Ki-67 < 20% (HR 0.62, p = 0.008), negative HER2 (HR 0.64, p < 0.0001), and with p53 wild-type IHC pattern (HR 0.71, p = 0.011) (Table 2, Figure 5). This evidence concerns the gene ERBB2 and breast cancer.